EBITDA Margin % is calculated as EBITDA divided by its Revenue. GlycoMimetics's EBITDA for the
three
months ended in Dec. 2023 was $-9.57 Mil. GlycoMimetics's Revenue for the
three
months ended in Dec. 2023 was $0.01 Mil. Therefore, GlycoMimetics's EBITDA margin for the quarter that ended in Dec. 2023 was -95,670.00%.
GlycoMimetics EBITDA Margin % Historical Data
The historical data trend for GlycoMimetics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of GlycoMimetics's EBITDA Margin %
For the Biotechnology subindustry, GlycoMimetics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlycoMimetics's EBITDA Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GlycoMimetics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where GlycoMimetics's EBITDA Margin % falls into.
GlycoMimetics EBITDA Margin % Calculation
EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.
GlycoMimetics's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
GlycoMimetics EBITDA Margin % Related Terms
Thank you for viewing the detailed overview of GlycoMimetics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
GlycoMimetics (GlycoMimetics) Business Description
GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GLYC has been successfully added to your 